Correction to: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas (Nature Medicine, (2009), 15, 12, (1369-1376), 10.1038/nm.2059);A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

Nature Medicine

Volumn 15, Issue 12, 2009, Pages 1369-1376

  Cerchietti, Leandro C ^a   Lopes, Eloisi C ^b   Yang, Shao Ning ^a   Hatzi, Katerina ^a   Bunting, Karen L ^a   Tsikitas, Lucas A ^a   Mallik, Alka ^a   Robles, Ana I ^c   Walling, Jennifer ^d   Varticovski, Lyuba ^c   Shaknovich, Rita ^a   Bhalla, Kapil N ^e   Chiosis, Gabriela ^b   Melnick, Ari ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Laboratory of Human Carcinogenesis   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA 2 MICROGLOBULIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE H3; I KAPPA B KINASE GAMMA; MESSENGER RNA; MUTANT PROTEIN; PROTEIN BCL 6; PROTEIN KINASE B; PU H71; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL NUCLEUS; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA STABILITY; TREATMENT RESPONSE;

EID: 71549121697     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-024-02957-0     Document Type: Erratum

References (37)

1. Neckers, L. Heat shock protein 90: the cancer chaperone. J. Biosci. 32, 517-530 (2007).
2. Wandinger, S.K., Richter, K. & Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 283, 18473-18477 (2008).
3. Bonvini, P., Gastaldi, T., Falini, B. & Rosolen, A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK+ CD30+ lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res. 62, 1559-1566 (2002).
4. Nimmanapalli, R., O'Bryan, E. & Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61, 1799-1804 (2001).
5. Chiosis, G. et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8, 289-299 (2001).
6. Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA 106, 8368-8373 (2009).
7. Taldone, T., Gozman, A., Maharaj, R. & Chiosis, G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 373-374 (2008).
8. Chiosis, G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 6, 1183-1191 (2006) (Pubitemid 44110929).
9. Chiosis, G. et al. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets 3, 371-376 (2003).
10. Chiosis, G., Lucas, B., Shtil, A., Huezo, H. & Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10, 3555-3564 (2002).
11. He, H. et al. Identifcation of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 49, 381-390 (2006).
12. Chiosis, G., Rodina, A. & Moulick, K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer. Agents Med. Chem. 6, 1-8 (2006) (Pubitemid 43796652).
13. Klein, U. & Dalla-Favera, R. Germinal centres: role in B cell physiology and malignancy. Nat. Rev. Immunol. 8, 22-33 (2008).
14. Ci, W., Polo, J.M. & Melnick, A. B cell lymphoma 6 and the molecular pathogenesis of diffuse large B cell lymphoma. Curr. Opin. Hematol. 15, 381-390 (2008).
15. Phan, R.T. & Dalla-Favera, R. The BCL-6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639 (2004).
16. Ranuncolo, S.M. et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 8, 705-714 (2007).
17. Cerchietti, L.C. et al. A peptomimetic inhibitor of BCL-6 with potent antilymphoma effects in vitro and in vivo. Blood 113, 3397-3405 (2009).
18. Polo, J.M. et al. Specifc peptide interference reveals BCL-6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10, 1329-1335 (2004).
19. Valbuena, J.R. et al. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod. Pathol. 18, 1343-1349 (2005).
20. Monti, S. et al. Molecular profling of diffuse large B cell lymphoma identifes robust subtypes including one characterized by host infammatory response. Blood 105, 1851-1861 (2005).
21. Polo, J.M. et al. Transcriptional signature with differential expression of BCL-6 target genes accurately identifes BCL-6-dependent diffuse large B cell lymphomas. Proc. Natl. Acad. Sci. USA 104, 3207-3212 (2007).
22. Schulte, T.W., Blagosklonny, M.V., Ingui, C. & Neckers, L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem. 270, 24585-24588 (1995).
23. Sato, S., Fujita, N. & Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97, 10832-10837 (2000).
24. Broemer, M., Krappmann, D. & Scheidereit, C. Requirement of Hsp90 activity for IKB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-KB activation. Oncogene 23, 5378-5386 (2004).
25. Niu, H., Ye, B.H. & Dalla-Favera, R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 12, 1953-1961 (1998).
26. Laroia, G., Cuesta, R., Brewer, G. & Schneider, R.J. Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 284, 499-502 (1999) (Pubitemid 29289625).
27. Wax, S., Piecyk, M., Maritim, B. & Anderson, P. Geldanamycin inhibits the production of infammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum. 48, 541-550 (2003).
28. Sinsimer, K.S. et al. Chaperone Hsp27, a novel subunit of AUF1 protein complexes, functions in AU-rich element-mediated mRNA decay. Mol. Cell. Biol. 28, 5223-5237 (2008).
29. Dean, J.L., Sully, G., Clark, A.R. & Saklatvala, J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell. Signal. 16, 1113-1121 (2004).
30. Ing, N.H., Massuto, D.A. & Jaeger, L.A. Estradiol up-regulates AUF1p45 binding to stabilizing regions within the 3'-untranslated region of estrogen receptor a mRNA. J. Biol. Chem. 283, 1764-1772 (2008).
31. Bakheet, T., Frevel, M., Williams, B.R., Greer, W. & Khabar, K.S. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 29, 246-254 (2001).
32. Liu, J. & DeFranco, D.B. Chromatin recycling of glucocorticoid receptors: implications for multiple roles of heat shock protein 90. Mol. Endocrinol. 13, 355-365 (1999).
33. Abu-Farha, M. et al. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics 7, 560-572 (2008).
34. Zhao, R. & Houry, W.A. Hsp90: a chaperone for protein folding and gene regulation. Biochem. Cell Biol. 83, 703-710 (2005).
35. Shinozaki, F. et al. Depletion of hsp90beta induces multiple defects in B cell receptor signaling. J. Biol. Chem. 281, 16361-16369 (2006).
36. Abramson, J.S. et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br. J. Haematol. 144, 358-366 (2009).
37. Robles, A.I. et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin. Cancer Res. 12, 6547-6556 (2006)